sorbitol has been researched along with canagliflozin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, SH; Kim, GW | 1 |
| Castellino, P; Fatuzzo, P; Granata, A; Lentini, P; Rapisarda, F; Rastelli, S; Zanoli, L | 1 |
| Shyangdan, DS; Uthman, OA; Waugh, N | 1 |
| Imamura, M; Kurosaki, E; Tahara, A; Takasu, T; Yokono, M | 1 |
| Kishimoto, M; Ohta, M; Suzuki, H; Takenaka, T; Tomonaga, O | 1 |
| Inoue, D; Inoue, R; Nangaku, M; Nishi, H | 1 |
3 review(s) available for sorbitol and canagliflozin
| Article | Year |
|---|---|
Clinical implication of SGLT2 inhibitors in type 2 diabetes.
Topics: Administration, Oral; Benzhydryl Compounds; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes | 2014 |
Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.
Topics: Animals; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol | 2015 |
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
Topics: Bayes Theorem; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Weight Loss | 2016 |
3 other study(ies) available for sorbitol and canagliflozin
| Article | Year |
|---|---|
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Mice, Inbred ICR; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes; Tissue Distribution | 2016 |
Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy.
Topics: Albuminuria; Biomarkers; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Canagliflozin; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Male; Medical Records; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Time Factors; Treatment Outcome | 2017 |
Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiologists; Cardiovascular System; Data Analysis; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Kidney; Male; Prescriptions; Regression Analysis; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes | 2021 |